293 related articles for article (PubMed ID: 29388013)
1. Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.
Pelosi G; Bianchi F; Dama E; Simbolo M; Mafficini A; Sonzogni A; Pilotto S; Harari S; Papotti M; Volante M; Fontanini G; Mastracci L; Albini A; Bria E; Calabrese F; Scarpa A
Virchows Arch; 2018 Apr; 472(4):567-577. PubMed ID: 29388013
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
3. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
Schnabel PA; Junker K
Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations of neuroendocrine tumours of the lung.
Rossi G; Bertero L; Marchiò C; Papotti M
Histopathology; 2018 Jan; 72(1):142-152. PubMed ID: 29239031
[TBL] [Abstract][Full Text] [Related]
5. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
[TBL] [Abstract][Full Text] [Related]
6. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
[TBL] [Abstract][Full Text] [Related]
7. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
[TBL] [Abstract][Full Text] [Related]
8. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.
Travis WD
Thorac Surg Clin; 2014 Aug; 24(3):257-66. PubMed ID: 25065926
[TBL] [Abstract][Full Text] [Related]
9. Advances in neuroendocrine lung tumors.
Travis WD
Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
[TBL] [Abstract][Full Text] [Related]
10. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
[TBL] [Abstract][Full Text] [Related]
13. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
[TBL] [Abstract][Full Text] [Related]
14. Bronchopulmonary neuroendocrine tumors.
Gustafsson BI; Kidd M; Chan A; Malfertheiner MV; Modlin IM
Cancer; 2008 Jul; 113(1):5-21. PubMed ID: 18473355
[TBL] [Abstract][Full Text] [Related]
15. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
16. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.
Vollbrecht C; Werner R; Walter RF; Christoph DC; Heukamp LC; Peifer M; Hirsch B; Burbat L; Mairinger T; Schmid KW; Wohlschlaeger J; Mairinger FD
Br J Cancer; 2015 Dec; 113(12):1704-11. PubMed ID: 26645239
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence.
Grøndahl V; Binderup T; Langer SW; Petersen RH; Nielsen K; Kjaer A; Federspiel B; Knigge U
Lung Cancer; 2019 Jun; 132():141-149. PubMed ID: 31097087
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
